Century Therapeutics
- Founded: 2018
- Location: Philadelphia, PA
- Employee range: 50 - 200
- Clinical stage: Clin1
- Therapy area: B-cell lymphomas
- Drug types: ONC
- Lead product: CNTY-101
- Product link: https://www.centurytx.com/pipeline/
- Funding: $242M IPO Jun 2021; $160M Mar 2021; $250M Jul 2019
- Investors: Bayer, Versant Ventures, Fujifilm Cellular Dynamics
centurytx.com linkedin.com job board
Short description:
iPSC Therapy platform
Drug notes:
CNTY-102 Clin0 B-cell malignancies; CNTY-104 RD AML; CNTY-106 Clin0 multiple myeloma; CNTY-107 RD solid tumors; undisclosed RD multiple cancers
Long description:
Century Therapeutics is using the power of adult stem cells to develop curative cell therapies for cancer. Induced pluripotent stem cells (iPSCs) have the potential to be turned into different cell types, including immune cells such as natural killer (NK) and T cells. Century has developed a cell therapy platform to generate allogeneic, iPSC-derived NK and T cell products. The platform involves gene editing, protein engineering and manufacturing to generate cell therapy products that can be dosed as needed until a patient receives a durable response. Currently, Century is furthest ahead with products for B-cell malignancies, but their products can be used to treat both hematological and solid tumor malignancies.
© 2024 Work In Biotech LLC
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com
Personal dataTerms of ServicePrivacy PolicyContact: recruit@workinbiotech.com